A comprehensive view of Takeda Pharmaceutical Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Kao Industrial, Takeda sign Thailand Dengue Prevention and Control memorandum of understanding; collaboration aims to cover all 50 districts in Bangkok and extend to other provinces nationwide to raise awareness about Dengue fever, increase prevention

MHRA raises concerns with switching between long-acting J&J, Novartis and Takeda drugs to treat attention-deficit/hyperactivity disorder

Puma Biotechnology to license Japanese drug firm Takeda’s experimental oral drug alisertib used to treat breast and lung cancers in deal worth up to US$294.0M; Puma to be responsible for global development, commercialization of the drug

Takeda’s injectable Takhzyro lanadelumab-flyo now available in US in single-dose prefilled syringes to prevent attacks of hereditary angioedema in adult, pediatric patients 12 years of age and older; HAE affects 1 in 50,000 people worldwide

Takeda announces approval in Japan for TAKHZYRO subcutaneous injection for prevention of acute attacks of hereditary angioedema; condition is a rare genetic disorder that causes recurring swelling

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count